Back to company

ELDON BIOLOGICALS A/S: Financial statements 2023

CVR: 26747007

ELDON BIOLOGICALS A/S (CVR 26747007) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 12,307,390 and a net result of DKK 5,362,663 compared with DKK 4,971,816 the year before. That is a decrease of 24.9% compared with the year before. Equity amounted to DKK 34,481,953. The solvency ratio was 87.1%. The company had 10 employees in the financial year.

Gross Profit
12,307,390 kr.
Profit/Loss
5,362,663 kr.
Equity
34,481,953 kr.
Total Assets
39,587,627 kr.
Employees
10

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2023-12.3 mio.5.4 mio.34.5 mio.10
2022-16.4 mio.5 mio.29.6 mio.9
2021-19.5 mio.9.1 mio.25.1 mio.11
2020-14.3 mio.6.6 mio.16.5 mio.8
2019-9.5 mio.3.3 mio.10.5 mio.6

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.

See the API documentation

About ELDON BIOLOGICALS A/S

ELDON BIOLOGICALS A/S is a Danish company of the type Aktieselskab based in Gentofte, founded in 2002. The company is registered under the industry Fremstilling af andre kemiske produkter i.a.n.. The management consists of Kasper Juul Hedegaard. The company is owned by MEDI-TRADE ApS and HOLDINGSELSKABET MLH ApS. The company has 9 employees. In 2025, the company reported a gross profit of DKK 13,635,058 and a net result of DKK 3,900,353 compared with DKK 6,673,643 the year before. Equity amounted to DKK 42,055,949.